Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes

INTRODUCTION: There are currently no guidelines for switching patients from oral risperidone to paliperidone palmitate (Invega Sustenna®). Furthermore, the paliperidone long-acting injectable (LAI) package insert does not recommend bridging with oral antipsychotics, which may result in inadequate se...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsia, Stephanie L., Leckband, Susan G., Rao, Sanjai, Jackson, Elizabeth, Lacro, Jonathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Innovative Practices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007563/
https://www.ncbi.nlm.nih.gov/pubmed/29955505
http://dx.doi.org/10.9740/mhc.2017.05.095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007563/
https://www.ncbi.nlm.nih.gov/pubmed/29955505
http://dx.doi.org/10.9740/mhc.2017.05.095

Ejemplares similares